Editorial Comment
January 2005
in “
Urology
”
TLDR Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
The study demonstrated that alfuzosin 10 mg significantly reduced the need for surgery after one episode of successful trial without catheter (TWOC), but the benefits declined over time, with no significant risk reduction at 6 months. This was similar to the MTOPS trial, where doxazosin delayed surgery but did not significantly reduce long-term surgery incidence. The findings suggested that combination therapy with an alpha-blocker and 5-alpha-reductase inhibitor could be effective in preventing acute urinary retention (AUR) and surgery. Tamsulosin, another alpha-blocker, was expected to perform similarly in TWOC after AUR.